![](https://investorshub.advfn.com/uicon/40490.png?cb=1674047870)
Wednesday, May 10, 2023 6:25:10 PM
Introduction
IMC-1 is a small molecule drug that is being developed for the treatment of fibromyalgia. It is a selective inhibitor of the enzyme cyclooxygenase-2 (COX-2), which is involved in the production of inflammatory mediators. IMC-1 has been shown to be effective in preclinical studies, and it is currently in clinical trials.
Toxicology Studies
A series of toxicity studies have been conducted in animals to assess the safety of IMC-1. These studies have shown that IMC-1 is generally well-tolerated in animals. The most common side effects of IMC-1 are nausea, vomiting, and diarrhea. These side effects are usually mild and go away on their own.
Long-Term Toxicity Studies
Long-term toxicity studies have not been conducted in animals. However, the short-term toxicity studies suggest that IMC-1 is unlikely to have any long-term side effects.
Carcinogenicity
IMC-1 has not been tested for carcinogenicity. However, the preclinical studies suggest that IMC-1 is unlikely to be carcinogenic.
Reproductive Toxicity
IMC-1 has not been tested for reproductive toxicity. However, the preclinical studies suggest that IMC-1 is unlikely to have any adverse effects on fertility or pregnancy.
Mutagenicity
IMC-1 has not been tested for mutagenicity. However, the preclinical studies suggest that IMC-1 is unlikely to be mutagenic.
Adverse Drug Reactions
The most common side effects of IMC-1 are nausea, vomiting, and diarrhea. These side effects are usually mild and go away on their own. Other side effects that have been reported include headache, fatigue, and rash.
Drug Interactions
IMC-1 has not been studied for drug interactions. However, it is important to tell your doctor about all of the medications you are taking, including over-the-counter medications, herbal supplements, and vitamins.
Overdose
There is no information available about the effects of an overdose of IMC-1. However, if you think you have taken too much IMC-1, call your doctor or the Poison Control Center immediately.
Precautions
IMC-1 should not be used in pregnant women or women who are trying to become pregnant. IMC-1 should also not be used in women who are breastfeeding.
IMC-1 should be used with caution in people with liver or kidney disease.
IMC-1 should not be used in people with a history of allergies to IMC-1 or any of its ingredients.
Conclusion
The toxicity studies conducted in animals suggest that IMC-1 is generally well-tolerated. The most common side effects of IMC-1 are nausea, vomiting, and diarrhea. These side effects are usually mild and go away on their own. Long-term toxicity studies have not been conducted in animals. However, the short-term toxicity studies suggest that IMC-1 is unlikely to have any long-term side effects. IMC-1 has not been tested for carcinogenicity, reproductive toxicity, mutagenicity, or drug interactions. However, the preclinical studies suggest that IMC-1 is unlikely to be carcinogenic, mutagenic, or have any adverse effects on fertility or pregnancy.
https://twitter.com/Nguyen/status/1656424151018553345
![Bullish](/static/images/ih2-bull.png)
Recent VIRI News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 01:15:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 01:15:20 PM
- Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study • GlobeNewswire Inc. • 05/22/2024 05:30:00 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/20/2024 08:05:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 01:28:00 PM
- Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study • GlobeNewswire Inc. • 05/20/2024 12:53:09 AM
- Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study • GlobeNewswire Inc. • 05/17/2024 08:10:00 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/17/2024 08:01:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 02:30:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:01:31 PM
- Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/09/2024 11:45:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 09:25:53 PM
- Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024 • GlobeNewswire Inc. • 05/02/2024 01:15:00 PM
- Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID • GlobeNewswire Inc. • 03/26/2024 01:15:00 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 03/08/2024 10:00:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:13 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/01/2024 02:10:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 02:25:17 PM
- Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 02/29/2024 02:15:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 06:14:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 06:01:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 05:56:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 05:54:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 05:51:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 05:47:41 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM